A systematic review of pharmacogenomic studies, published in the European Heart Journal, has provided an overview of how this discipline can be applied to clinical practice in the near future.
The paper outlines how previous studies exploring drug-gene interactions have led to the FDA adapting recommendations so they take into account the possible effects of heritable genetic polymorphisms have on drug therapy.
This paper summarises the current knowledge on the pharmacogenomics of all major drug classes used to treat cardiovascular diseases, providing a body of evidence that suggests we are on the verge of a radical overhaul in our approach towards cardiovascular pharmacotherapy.